52_CD Notes_NNS to_TO Group_NNP financial_JJ statements_NNS 31_CD DECEMBER_NNP 2003_CD 1_CD ACCOUNTING_NNP POLICIES_NNPS CONTINUED_VBD SHORT-TERM_JJ INVESTMENTS_NNP Bank_NNP deposits_NNS ,_, which_WDT are_VBP not_RB repayable_JJ on_IN demand_NN ,_, are_VBP treated_VBN as_IN short-term_JJ investments_NNS in_IN accordance_NN with_IN FRS1_CD ,_, Cash_NN flow_NN statements_NNS ._.
Movements_NNS in_IN such_JJ investments_NNS are_VBP included_VBN under_IN management_NN of_IN liquid_JJ resources_NNS in_IN the_DT Groups_NNS cash_NN flow_NN statement_NN ._.
STOCK_NN ,_, EXCLUDING_NNP LONG-TERM_JJ CONTRACTS_NNP Stock_NNP is_VBZ stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
In_IN general_JJ ,_, cost_NN is_VBZ determined_VBN on_IN a_DT first-in-first-out_JJ basis_NN and_CC includes_VBZ transport_NN and_CC handling_VBG costs_NNS ._.
Where_WRB necessary_JJ ,_, provision_NN is_VBZ made_VBN for_IN obsolete_JJ ,_, slow-moving_JJ or_CC defective_JJ stock_NN ._.
LEASES_NNP Assets_NNPS acquired_VBD under_IN finance_NN leases_NNS are_VBP included_VBN in_IN the_DT balance_NN sheet_NN as_IN tangible_JJ fixed_JJ assets_NNS and_CC are_VBP depreciated_VBN over_IN the_DT shorter_JJR of_IN the_DT lease_NN period_NN or_CC their_PRP$ useful_JJ lives_NNS ._.
The_DT capital_NN elements_NNS of_IN future_JJ lease_NN payments_NNS are_VBP recorded_VBN as_IN liabilities_NNS ,_, while_IN the_DT interest_NN elements_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT period_NN of_IN the_DT leases_NNS to_TO give_VB a_DT constant_JJ charge_NN on_IN the_DT balance_NN of_IN the_DT capital_NN repayments_NNS outstanding_JJ ._.
The_DT cost_NN of_IN operating_VBG leases_NNS is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT lease_NN term_NN ,_, even_RB if_IN rental_JJ payments_NNS are_VBP not_RB made_VBN on_IN such_PDT a_DT basis_NN ._.
FOREIGN_JJ CURRENCIES_NNS Transactions_NNS denominated_VBN in_IN foreign_JJ currencies_NNS are_VBP recorded_VBN in_IN the_DT local_JJ currency_NN at_IN actual_JJ exchange_NN rates_NNS as_RB at_IN the_DT date_NN of_IN the_DT transaction_NN ._.
Monetary_NNP assets_NNS and_CC liabilities_NNS denominated_VBN in_IN foreign_JJ currencies_NNS are_VBP translated_VBN at_IN the_DT rates_NNS ruling_VBG at_IN the_DT balance_NN sheet_NN date_NN ._.
Any_DT gain_NN or_CC loss_NN arising_VBG from_IN a_DT change_NN in_IN exchange_NN rates_NNS subsequent_JJ to_TO the_DT date_NN of_IN the_DT transaction_NN is_VBZ included_VBN as_IN an_DT exchange_NN gain_NN or_CC loss_NN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Assets_NNS and_CC liabilities_NNS of_IN overseas_JJ subsidiary_NN and_CC joint_JJ venture_NN undertakings_NNS are_VBP translated_VBN into_IN sterling_NN at_IN rates_NNS of_IN exchange_NN ruling_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT results_NNS and_CC cash_NN flows_NNS of_IN overseas_JJ subsidiary_NN and_CC joint_JJ venture_NN undertakings_NNS are_VBP translated_VBN into_IN sterling_NN using_VBG average_JJ rates_NNS of_IN exchange_NN ._.
Exchange_NNP adjustments_NNS arising_VBG when_WRB the_DT opening_NN net_JJ assets_NNS and_CC the_DT profits_NNS for_IN the_DT year_NN retained_VBN by_IN overseas_JJ subsidiary_NN and_CC joint_JJ venture_NN undertakings_NNS are_VBP translated_VBN into_IN sterling_NN are_VBP taken_VBN directly_RB to_TO reserves_NNS and_CC reported_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
Where_WRB financing_NN of_IN a_DT foreign_JJ subsidiary_NN through_IN long-term_JJ loans_NNS and_CC deferred_VBN trading_NN balances_NNS is_VBZ intended_VBN to_TO be_VB as_IN permanent_JJ as_IN equity_NN ,_, such_JJ loans_NNS and_CC inter-company_JJ balances_NNS are_VBP treated_VBN as_IN part_NN of_IN the_DT net_JJ investment_NN and_CC ,_, as_IN such_JJ ,_, any_DT exchange_NN differences_NNS arising_VBG are_VBP dealt_VBN with_IN as_IN adjustments_NNS to_TO reserves_NNS ._.
FINANCIAL_NNP INSTRUMENTS_NNP From_IN time_NN to_TO time_NN ,_, the_DT Group_NNP attempts_VBZ to_TO reduce_VB its_PRP$ foreign_JJ currency_NN exposure_NN using_VBG forward_RB planning_VBG of_IN currency_NN requirements_NNS for_IN US_NNP dollars_NNS and_CC UK_NNP sterling_NN ,_, and_CC entering_VBG into_IN forward_JJ rate_NN currency_NN contracts_NNS as_IN appropriate_JJ see_VBP note_NN 22_CD ._.
The_DT Group_NNP does_VBZ not_RB enter_VB into_IN any_DT other_JJ derivative_JJ transactions_NNS ._.
Forward_RB currency_NN contracts_NNS are_VBP valued_VBN by_IN taking_VBG the_DT difference_NN between_IN the_DT foreign_JJ currency_NN amount_NN of_IN the_DT forward_JJ contract_NN translated_VBN at_IN the_DT forward_JJ rate_NN at_IN the_DT date_NN of_IN inception_NN ,_, and_CC the_DT amount_NN translated_VBN at_IN the_DT balance_NN sheet_NN rate_NN ._.
The_DT Group_NNP makes_VBZ certain_JJ deposits_NNS in_IN foreign_JJ currencies_NNS for_IN fixed_VBN terms_NNS known_VBN as_IN dual_JJ currency_NN deposits_NNS ,_, which_WDT ,_, at_IN the_DT option_NN of_IN the_DT bank_NN mature_VBP in_IN that_DT foreign_JJ currency_NN or_CC are_VBP converted_VBN to_TO sterling_NN at_IN a_DT pre-agreed_JJ exchange_NN rate_NN ._.
These_DT deposits_NNS are_VBP translated_VBN at_IN the_DT lower_JJR of_IN the_DT exchange_NN rate_NN ruling_NN at_IN the_DT balance_NN sheet_NN date_NN and_CC the_DT pre-agreed_JJ rate_NN implicit_JJ in_IN the_DT contract_NN such_JJ that_IN the_DT deposit_NN is_VBZ held_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC market_NN value_NN ._.
Interest_NN is_VBZ recognized_VBN on_IN an_DT accruals_NNS basis_NN ._.
EMPLOYEE_NN SHARE_NN OPTION_NN SCHEMES_NNS In_IN accordance_NN with_IN Urgent_NNP Issues_NNP Task_NNP Force_NNP UITF_NNP Abstract_NNP 17_CD ,_, Employee_NNP Share_NNP Schemes_NNP UITF_NNP 17_CD ,_, the_DT cost_NN of_IN awards_NNS to_TO employees_NNS of_IN share_NN options_NNS is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT period_NN to_TO which_WDT the_DT performance_NN relates_VBZ ,_, based_VBN on_IN an_DT assessment_NN of_IN the_DT probability_NN of_IN the_DT performance_NN criteria_NNS being_VBG met_VBN ._.
The_DT cost_NN of_IN such_JJ awards_NNS is_VBZ calculated_VBN as_IN the_DT difference_NN between_IN the_DT fair_JJ value_NN of_IN the_DT shares_NNS at_IN the_DT date_NN of_IN the_DT grant_NN and_CC the_DT exercise_NN price_NN of_IN the_DT option_NN or_CC ,_, where_WRB awards_NNS are_VBP expected_VBN to_TO be_VB settled_VBN from_IN shares_NNS held_VBN by_IN the_DT Employee_NNP Share_NN Option_NN Plan_NN ESOP_NNP trust_NN ,_, as_IN the_DT difference_NN between_IN the_DT book_NN value_NN of_IN the_DT ESOP_NNP shares_NNS and_CC the_DT exercise_NN price_NN of_IN the_DT option_NN ._.
In_IN accordance_NN with_IN UITF_NNP Abstract_NNP 25_CD ,_, National_NNP Insurance_NNP contributions_NNS on_IN share_NN option_NN gains_NNS ,_, the_DT Group_NNP makes_VBZ charges_NNS to_TO the_DT profit_NN and_CC loss_NN account_NN for_IN the_DT potential_JJ employers_NNS National_NNP Insurance_NNP liability_NN on_IN options_NNS granted_VBN ,_, spread_VBN over_IN the_DT vesting_JJ period_NN of_IN those_DT options_NNS ._.
ESOP_NNP TRUST_NNP The_NNP Group_NNP will_MD adopt_VB the_DT provisions_NNS of_IN UITF_NNP 38_CD Accounting_NN for_IN ESOP_NNP Trusts_NNPS in_IN its_PRP$ next_JJ financial_JJ year_NN ._.
THE_DT INFORMATION_NNP IN_IN THIS_NNP BORDER_NNP HAS_VBZ NOT_RB BEEN_JJ AUDITED_JJ A_DT SEGMENTAL_NNP INFORMATION_NNP TURNOVER_NNP OUR_NNP TURNOVER_NNP REPRESENTS_VBZ PRODUCT_NN SALES_NNS AND_CC TO_TO OTHER_NNP FOREIGN_NNP GOVERNMENTS_NNPS :_: R&D_NN REVENUES_NNS FROM_IN REVENUES_NNS FROM_IN RESEARCH_NN AND_CC DEVELOPMENT_NNP CONTRACTS_NNS ._.
THE_DT NIAID_NNP IN_IN RESPECT_NNP OF_IN THE_DT MVA_NNP CONTRACT_NNP :_: R&D_NNP REVENUES_NNP THE_DT MAIN_NNP SOURCE_NNP OF_IN TURNOVER_NNP IN_IN 2003_CD AROSE_JJ FROM_IN THE_DT FROM_NNP AVENTIS_NNP PASTEUR_NNP ON_NNP OUR_NNP CHIMERIVAX-DENGUE_NNP 155_CD MILLION-DOSE_JJ ACAM2000_CD SMALLPOX_NNP VACCINE_NNP CONTRACT_NNP VACCINE_NNP PROGRAMME_NNP :_: AND_CC FOR_IN THE_DT FIRST_NNP TIME_NNP PRODUCT_NNP WITH_IN THE_DT CDC_NNP ._.
DURING_IN THE_DT YEAR_NN WE_VBD ALSO_RB RECORDED_VBN :_: SALES_NNS OF_IN VIVOTIF_NNP FOLLOWING_NNP THE_DT ACQUISITION_NNP OF_IN BPC_NNP REVENUE_NNP FROM_NNP THE_DT SALES_NNS OF_IN ACAM2000_CD SMALLPOX_NNP IN_IN AUGUST_NNP 2003_CD ._.
VACCINE_NN ,_, IN_IN CONJUNCTION_NNP WITH_IN OUR_NNP PARTNER_NNP BAXTER_NNP
